Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 12:9:169-77.
doi: 10.4137/cin.s5065.

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics

Affiliations

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics

D S Dalafave et al. Cancer Inform. .

Abstract

Informatics and computational design methods were used to create new molecules that could potentially bind antiapoptotic proteins, thus promoting death of cancer cells. Apoptosis is a cellular process that leads to the death of damaged cells. Its malfunction can cause cancer and poor response to conventional chemotherapy. After being activated by cellular stress signals, proapoptotic proteins bind antiapoptotic proteins, thus allowing apoptosis to go forward. An excess of antiapoptotic proteins can prevent apoptosis. Designed molecules that mimic the roles of proapoptotic proteins can promote the death of cancer cells. The goal of our study was to create new putative mimetics that could simultaneously bind several antiapoptotic proteins. Five new small molecules were designed that formed stable complexes with BCL-2, BCL-XL, and MCL-1 antiapoptotic proteins. These results are novel because, to our knowledge, there are not many, if any, small molecules known to bind all three proteins. Drug-likeness studies performed on the designed molecules, as well as previous experimental and preclinical studies on similar agents, strongly suggest that the designed molecules may indeed be promising drug candidates. All five molecules showed "drug-like" properties and had overall drug-likeness scores between 81% and 96%. A single drug based on these mimetics should cost less and cause fewer side effects than a combination of drugs each aimed at a single protein. Computer-based molecular design promises to accelerate drug research by predicting potential effectiveness of designed molecules prior to laborious experiments and costly preclinical trials.

Keywords: anticancer drug research; apoptosis; cancer; small molecule mimetics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Structures of the five designed small molecules, from left to right: C18H23N4, C16H15N6, C14H15N3O, C17H15N4, and C13H10N3. Color code: C-yellow, N-pink, O-green, H-white.
Figure 2.
Figure 2.
The MCL-1 binding groove is shown with designed small molecule C17H15N4 (red ball-and-stick). MCL-1 residues that bind Noxa and Puma, M212, V230, V234, T247, and F251, are shown as yellow solid spheres. Nearby MCL-1 residues are presented as purple solid spheres. To increase visibility of the small molecule and yellow residues, some MCL-1 residues are either presented as purple ball-and-stick or omitted.

Similar articles

Cited by

References

    1. Vaux DL, Cory S, Adams JM. Bcl-2 Gene Promotes Haemopoietic Cell Survival and Cooperates with C- Myc to Immortalize Pre-B Cells. Nature. 1988;335:440–2. - PubMed
    1. Campos L, Rouault JP, Sabido O, et al. High Expression of Bcl-2 Protein in Acute Myeloid Leukemia Cells is Associated with Poor Response to Chemotherapy. Blood. 1993;81:3091–6. - PubMed
    1. Waksman G, editor. Proteomics and Protein-Protein Interactions: Biology, Chemistry, Bioinformatics, and Drug Design. New York: Springer; 2005.
    1. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An Inhibitor of BCL-2 Family Proteins Induces Regression of Solid Tumours. Nature. 2005;435:677–81. - PubMed
    1. Kann MG. Protein Interactions and Disease: Computational Approaches to Uncover the Etiology of Diseases. Brief Bioinform. 2007;8:333–46. - PubMed